Alloy Therapeutics

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

Kent Bondensgaard

Senior Vice President - Antibody Discovery Services

Ross Leimberg

Venture Partner

9 past transactions

Wheeler Bio

Series A in 2025
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.

Wheeler Bio

Series A in 2022
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.

Vernal Biosciences

Venture Round in 2022
Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.

Tegmine Therapeutics

Corporate Round in 2022
Tegmine Therapeutics is a private, seed-stage biotechnology company focused on developing antibody-based therapeutics that target proteins and their disease-related glycan modifications. The company employs a unique platform that integrates biology, mass spectrometry, and machine learning to identify tumor-specific protein modifications responsible for disease progression and severity. This innovative approach aims to facilitate the creation of next-generation antibody drugs that are specifically designed to target tumors while minimizing damage to healthy tissues. Through its research and development efforts, Tegmine Therapeutics seeks to contribute to more sustainable cancer and tumor therapies, enhancing treatment efficacy and patient outcomes.

Mytide Therapeutics

Series A in 2022
Mytide specializes in peptide synthesis and purification, aiming to facilitate diverse applications. They collaborate with partners to tackle challenges in peptide production, identify useful modifications, and design peptide libraries. Mytide offers a cloud platform for immediate ordering, properties calculation, order tracking, and interactive data display.

Wheeler Bio

Seed Round in 2022
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.

deepCDR Biologics

Acquisition in 2021
deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Wheeler Bio

Funding Round in 2021
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.

Vernal Biosciences

Seed Round in 2021
Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.